Main information



  • Available in:
  • Language:
  • English

Other information


  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 218860
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:



ARTG entry for

Medicine Listed


Shen Neng Herbal Medicines Group Pty Ltd

Postal Address

1 Clarke Street,GUILDFORD, NSW, 2161


ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

Sponsors must confirm the absence of aristolochic acids, or herbal species known to contain these acids, in all medicines containing herbal material

derived from any of the following plant genera - Akebia, Asarum, Bragantia, Clematis, Cocculus, Diploclisia, Menispernum, Saussurea, Sinomenium,

Stephania, Vladimiria.Such confirmation is to be provided to The Director, Complementary Medicines Branch, TGA prior to supply of each batch in

Australia and may take the form of EITHER chemical analysis OR botanical identification as detailed below.Chemical Analysis: This requires the

provision of a certificate of chemical analysis, including raw data generated in the analysis, to the TGA. Each batch of product is to be accompanied by a

Certificate of Analysis confirming the absence of aristolochic acids and including raw data supporting the results. The Certificate and all supporting

evidence must be approved by the TGA prior to supply of the batch in Australia. Methodology used to perform the chemical analysis is to be, at least,

equivalent to the method developed by the FDA in terms of specificity and limits of detection. If methodology other than that of the FDA is used, the

alternative methods are to be submitted to the TGA for approval prior to implementation. All relevant details of the methodology, such as analytical

method validation data, are to be included in the submission. Botanical Identification: This requires the provision of evidence of the botanical

identification of herbal material from any of the affected genera to the TGA, prior to supply of each batch of goods in Australia. This evidence is to be

comprised of a Certificate of Identification, plus information regarding the signatory including full name, contact information and details of qualifications

and experience relevant to the task of identification of botanical material.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.



Product Type

Single Medicine Product

Effective date



(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].

Products containing activated charcoal should be used with caution in children since it may interfere with absorption of nutrients. Activated charcoal may

interact with other medicines. Activated charcoal is not recommended for long-term use. [or words to that effect]

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Relief of sinus pain. [Warning S required]

By drying the secretions of the nose, this nasal decongestant product makes breathing easier. [Warning S required]

Relief of symptoms of mild upper respiratory infections. [Warnings S and COLD required]

Relief of mucous congestion. [Warnings S and COLD required]

Relief of sinusitis. [Warning S required]

Specific Indications

No Specific Indications included on Record

Public Summary

Page 1 of

Produced at 26.11.2017 at 04:19:15 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule


1. Formulation 1

Dosage Form


Route of Administration


Visual Identification

Active Ingredients

Actaea heracleifolia

2.78 mg

Equivalent: Actaea heracleifolia (Dry)

41.3 mg

Angelica dahurica

49.3 mg

Equivalent: Angelica dahurica (Dry)

49.3 mg

Clematis armandii

2.78 mg

Equivalent: Clematis armandii (Dry)

41.3 mg

Glycyrrhiza uralensis

32.2 mg

Equivalent: Glycyrrhiza uralensis (Dry)

32.2 mg

Ligusticum sinense

2.78 mg

Equivalent: Ligusticum sinense (Dry)

41.3 mg

Ligusticum striatum

41.3 mg

Equivalent: Ligusticum striatum (Dry)

41.3 mg

Magnolia liliflora

3.86 mg

Equivalent: Magnolia liliflora (Dry)

57.3 mg

Notopterygium incisium

2.17 mg

Equivalent: Notopterygium incisium (Dry)

32.2 mg

Saposhnikovia divaricata

2.78 mg

Equivalent: Saposhnikovia divaricata (Dry)

41.3 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 2 of

Produced at 26.11.2017 at 04:19:15 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information